The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Efectin     1-[2-dimethylamino-1-(4...

Synonyms: Elafax, Venlafaxin, Venlafaxina, Venlafexine, venlafaxine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07187


Psychiatry related information on C07187


High impact information on C07187

  • OBJECTIVE: To compare the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in outpatients with GAD without associated MDD [4].
  • RESULTS: In the entire cohort, fluoxetine use was associated with the lowest risk (RR, 0.52; 95% confidence interval [CI], 0.30-0.93), and venlafaxine hydrochloride use with the highest risk (RR, 1.61; 95% CI, 1.01-2.57), of suicide [10].
  • CONCLUSIONS: This preliminary investigation has shown limbic blood flow increase with IPT yet not venlafaxine, while both treatments demonstrated increased basal ganglia blood flow [11].
  • RESULTS: Both treatment groups improved substantially, more so with venlafaxine (mean [SD] HAM-D scores at pretreatment: IPT, 22.7 [2.7], and venlafaxine, 22.4 [3.1]; and posttreatment: IPT, 16.2 [7.1], and venlafaxine, 10.9 [8.6]) [11].
  • Statistically significant changes in height, weight, blood pressure, pulse, and cholesterol levels were observed in the extended-release venlafaxine group [12].

Chemical compound and disease context of C07187


Biological context of C07187


Anatomical context of C07187


Associations of C07187 with other chemical compounds

  • METHOD: Adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or had withdrawn from treatment because of intolerance in three previous prospective medication trials were randomly assigned to receive open-label treatment with either tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51) [26].
  • METHODS: One hour after subcutaneous injection of venlafaxine, paroxetine, mirtazapine, or doxepin, knockout and wildtype mice were sacrificed, and the drug concentrations in brain, spleen, kidney, liver, and plasma were measured [27].
  • Selectively, compared with control subjects bupropion responders (n = 6) also had cerebellar hypermetabolism, whereas venlafaxine responders (n = 7) showed bilateral temporal and basal ganglia hypometabolism [6].
  • Apparent total clearance of venlafaxine and O-desmethylvenlafaxine were both significantly decreased by approximately 55% in the subjects receiving dialysis, and terminal disposition half-life was significantly prolonged for both compounds [28].
  • RESULTS: Patients (n = 9) receiving venlafaxine showed a significant decrease (42%) in their CSF 5-HIAA concentrations after treatment, but no change in other CSF measures [29].

Gene context of C07187


Analytical, diagnostic and therapeutic context of C07187


  1. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., LaVasseur, B.I., Barton, D.L., Novotny, P.J., Dakhil, S.R., Rodger, K., Rummans, T.A., Christensen, B.J. Lancet (2000) [Pubmed]
  2. Neuroleptic malignant syndrome after venlafaxine. Nimmagadda, S.R., Ryan, D.H., Atkin, S.L. Lancet (2000) [Pubmed]
  3. Treatment of chronic fatigue syndrome with venlafaxine. Goodnick, P.J. The American journal of psychiatry. (1996) [Pubmed]
  4. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Gelenberg, A.J., Lydiard, R.B., Rudolph, R.L., Aguiar, L., Haskins, J.T., Salinas, E. JAMA (2000) [Pubmed]
  5. Venlafaxine in obsessive-compulsive disorder. Yaryura-Tobias, J.A., Neziroglu, F.A. Arch. Gen. Psychiatry (1996) [Pubmed]
  6. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Little, J.T., Ketter, T.A., Kimbrell, T.A., Dunn, R.T., Benson, B.E., Willis, M.W., Luckenbaugh, D.A., Post, R.M. Biol. Psychiatry (2005) [Pubmed]
  7. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Enggaard, T.P., Klitgaard, N.A., Gram, L.F., Arendt-Nielsen, L., Sindrup, S.H. Clin. Pharmacol. Ther. (2001) [Pubmed]
  8. Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. Pinna, G., Broedel, O., Eravci, M., Stoltenburg-Didinger, G., Plueckhan, H., Fuxius, S., Meinhold, H., Baumgartner, A. Biol. Psychiatry (2003) [Pubmed]
  9. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. March, J.S., Entusah, A.R., Rynn, M., Albano, A.M., Tourian, K.A. Biol. Psychiatry (2007) [Pubmed]
  10. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Tiihonen, J., L??nnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., Haukka, J. Arch. Gen. Psychiatry (2006) [Pubmed]
  11. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Martin, S.D., Martin, E., Rai, S.S., Richardson, M.A., Royall, R. Arch. Gen. Psychiatry (2001) [Pubmed]
  12. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Rynn, M.A., Riddle, M.A., Yeung, P.P., Kunz, N.R. The American journal of psychiatry (2007) [Pubmed]
  13. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Liebowitz, M.R., Gelenberg, A.J., Munjack, D. Arch. Gen. Psychiatry (2005) [Pubmed]
  14. Blood pressure changes during short-term fluoxetine treatment. Amsterdam, J.D., Garcia-Espana, F., Fawcett, J., Quitkin, F.M., Reimherr, F.W., Rosenbaum, J.F., Beasley, C. Journal of clinical psychopharmacology. (1999) [Pubmed]
  15. The role of venlafaxine in rational antidepressant therapy. Feighner, J.P. The Journal of clinical psychiatry. (1994) [Pubmed]
  16. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Davidson, J., Rothbaum, B.O., Tucker, P., Asnis, G., Benattia, I., Musgnung, J.J. Journal of clinical psychopharmacology. (2006) [Pubmed]
  17. Contemporary management of depression. Andrews, J.M., Nemeroff, C.B. Am. J. Med. (1994) [Pubmed]
  18. Venlafaxine and breast-feeding. Hendrick, V., Altshuler, L., Wertheimer, A., Dunn, W.A. The American journal of psychiatry. (2001) [Pubmed]
  19. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Einarson, A., Fatoye, B., Sarkar, M., Lavigne, S.V., Brochu, J., Chambers, C., Mastroiacovo, P., Addis, A., Matsui, D., Schuler, L., Einarson, T.R., Koren, G. The American journal of psychiatry. (2001) [Pubmed]
  20. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Gould, G.G., Altamirano, A.V., Javors, M.A., Frazer, A. Biol. Psychiatry (2006) [Pubmed]
  21. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, S.H., McCann, S.M., Masellis, M., McIntyre, R.S., Raskin, J., McKay, G., Baker, G.B. The Journal of clinical psychiatry. (2002) [Pubmed]
  22. Antidepressants in amniotic fluid: another route of fetal exposure. Loughhead, A.M., Fisher, A.D., Newport, D.J., Ritchie, J.C., Owens, M.J., DeVane, C.L., Stowe, Z.N. The American journal of psychiatry. (2006) [Pubmed]
  23. The response of synaptophysin and microtubule-associated protein 1 to restraint stress in rat hippocampus and its modulation by venlafaxine. Xu, H., He, J., Richardson, J.S., Li, X.M. J. Neurochem. (2004) [Pubmed]
  24. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I., Greenblatt, D.J. Neuropsychopharmacology (1999) [Pubmed]
  25. Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Lang, E., Hord, A.H., Denson, D. Pain (1996) [Pubmed]
  26. Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. McGrath, P.J., Stewart, J.W., Fava, M., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Thase, M.E., Davis, L., Biggs, M.M., Shores-Wilson, K., Luther, J.F., Niederehe, G., Warden, D., Rush, A.J. The American journal of psychiatry. (2006) [Pubmed]
  27. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Uhr, M., Grauer, M.T., Holsboer, F. Biol. Psychiatry (2003) [Pubmed]
  28. The effect of renal disease on the disposition of venlafaxine. Troy, S.M., Schultz, R.W., Parker, V.D., Chiang, S.T., Blum, R.A. Clin. Pharmacol. Ther. (1994) [Pubmed]
  29. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Little, J.T., Ketter, T.A., Mathé, A.A., Frye, M.A., Luckenbaugh, D., Post, R.M. Biol. Psychiatry (1999) [Pubmed]
  30. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Eap, C.B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M.A., O'Hara, G., Turgeon, J. Pharmacogenetics (2003) [Pubmed]
  31. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D., Pollmächer, T. Pharmacopsychiatry (2002) [Pubmed]
  32. Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats. Chen, Z., Xu, H., Haimano, S., Li, X., Li, X.M. Neurosci. Lett. (2005) [Pubmed]
  33. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Fukuda, T., Nishida, Y., Zhou, Q., Yamamoto, I., Kondo, S., Azuma, J. Eur. J. Clin. Pharmacol. (2000) [Pubmed]
  34. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Owen, J.R., Nemeroff, C.B. Depression and anxiety. (1998) [Pubmed]
  35. The neural substrates of affective processing in depressed patients treated with venlafaxine. Davidson, R.J., Irwin, W., Anderle, M.J., Kalin, N.H. The American journal of psychiatry. (2003) [Pubmed]
  36. Antidepressants and periodic leg movements of sleep. Yang, C., White, D.P., Winkelman, J.W. Biol. Psychiatry (2005) [Pubmed]
WikiGenes - Universities